SYSTEMATIC REVIEW article
Front. Neurol.
Sec. Neuromuscular Disorders and Peripheral Neuropathies
Efficacy and Safety of Anti-CD20 Monoclonal Antibody Therapy for Autoimmune Nodopathies: A Systematic Review and Meta-analysis
Provisionally accepted
- 1Jiangsu University School of Medicine, Zhenjiang, China
- 2The First Clinical Medical College, Hubei University of Medicine, Shiyan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Autoimmune nodopathy (AN) is a distinct CIDP-like entity defined by its poor response to standard treatments, including IVIG. The efficacy and safety of anti-CD20 monoclonal antibodies, a potential mechanism-based therapy, have not been quantitatively synthesized. Objective To systematically evaluate and quantitatively synthesize the efficacy and safety of anti-CD20 monoclonal antibody therapy in patients with AN. Methods A comprehensive literature search was conducted across PubMed, Web of Science, Cochrane Library, Embase, and ClinicalTrials.gov from inception to August 4, 2025. Studies reporting clinical outcomes of AN patients treated with anti-CD20 agents were included. A generalized linear mixed model (GLMM) was employed to estimate pooled response rates. Results Twenty-nine studies comprising 118 patients were included. In the descriptive synthesis, most reports described physician-assessed clinical improvement after anti-CD20 therapy. For quantitative pooling, we restricted the meta-analysis to studies reporting standardized, objective scale-based outcomes (n=100), yielding a pooled clinical response rate of 92.0% (95% CI: 84.8%–95.9%; I²=0%). Subgroup analyses demonstrated sustained responsiveness in patients with anti-NF155 (95.2%) and anti-CNTN1 (88.9%) autoantibodies. Adverse events were recorded in 8.5% of patients (10/118), primarily consisting of mild infusion-related reactions. However, two fatalities (1.7%) associated with severe infection or comorbidities were noted. Conclusion Anti-CD20 therapy has shown high efficacy in treating AN that is refractory to conventional treatments. However, due to the observational nature of the available data and the lack of randomized controlled trials, these results should be interpreted with caution and are not yet practice-changing. Further prospective, controlled studies are needed to better define the treatment's efficacy, optimal dosing strategies, and long-term safety.
Keywords: Anti-CD20 monoclonal antibody, Autoimmune nodopathy, Chronic inflammatory demyelinating polyradiculoneuropathy, Contactin1, Meta-analysis, neurofascin-155, Ofatumumab, rituximab
Received: 02 Dec 2025; Accepted: 09 Feb 2026.
Copyright: © 2026 Tao, Jiang, Gui and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jie Ma
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.